Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate to severe plaque psoriasis.

Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate to severe plaque psoriasis. J Med Econ. 2019 Jun 14;:1 Authors: Teeple A, Muser E Abstract Aims: To estimate annual cost per response (CPR) in the US and number needed to treat (NNT) among subjects receiving guselkumab or adalimumab treatment for moderate to severe plaque psoriasis (PsO). Materials and methods: Results from VOYAGE 1, a double-blind, placebo-controlled, head-to-head, 48-week study of guselkumab compared with adalimumab in patients with moderate to severe PsO were used to estimate annual CPR for Psoriasis Area and Severity Index (PASI) 75, 90 and 100 responses. Drug dosing followed US label recommendations and drug costs were based on US annual wholesale acquisition costs. Number needed to treat (NNT) and annual CPR analyses were estimated, and week 48 response rates were assumed to be maintained for both the induction and maintenance years. Results: Week-48 PASI 90 response rates were 76.3% for guselkumab and 47.9% for adalimumab. The CPR for PASI 90 in the induction year for guselkumab was $106,511 versus $142,398 for adalimumab. Both drugs had lower CPRs for PASI 90 in the maintenance year: $79,884 for guselkumab and $132,227 for adalimumab. The NNT for a PASI 90 response was 1.3 for guselkumab and 2.1 for adalimumab; CPRs and NNT were also lower for guselkumab than for adalimumab for PASI 75 and...
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research